Paxil® (Paroxetine HCl) - a registered trademark of GlaxoSmithKline - is a psychotropic drug indicated for the treatment of major depressive disorder, panic disorder, obsessive compulsive disorder, social anxiety disorder, generalized anxiety disorder, and posttraumatic stress disorder.

Now, a generic bioequivalent of the product has been approved by the FDA: Caraco Pharmaceuticals Laboratories, Ltd.'s paroxetine hydrochloride tablets, USP (Paroxetine HCl).

According to Daniel H. Movens, Caraco's Chief Executive Officer:

"We are pleased to gain this approval as it complements our portfolio and fortifies our product offering by expanding our product line. We plan to market this product to the generic pharmaceutical market immediately. This will bring our total product selection to 34 different products represented by 70 various strengths."

Read the full report.

[Photo Credit: MSNBC]